The stock of Regulus Therapeutics Inc (RGLS) has seen a -0.19% decrease in the past week, with a 304.90% gain in the past month, and a 549.17% flourish in the past quarter. The volatility ratio for the week is 0.83%, and the volatility levels for the past 30 days are at 6.49% for RGLS. The simple moving average for the past 20 days is 29.32% for RGLS’s stock, with a 301.25% simple moving average for the past 200 days.
Is It Worth Investing in Regulus Therapeutics Inc (NASDAQ: RGLS) Right Now?
Additionally, the 36-month beta value for RGLS is 0.36. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for RGLS is 57.25M and currently, short sellers hold a 4.73% ratio of that float. The average trading volume of RGLS on May 16, 2025 was 1.89M shares.
RGLS) stock’s latest price update
Regulus Therapeutics Inc (NASDAQ: RGLS) has experienced a rise in its stock price by 0.06 compared to its previous closing price of 7.85. However, the company has seen a fall of -0.19% in its stock price over the last five trading days. prnewswire.com reported 2025-05-08 that Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right (“CVR”) upon the achievement of a regulatory milestone, for a total equity value of up to approximately $1.7 billion; Expected to be completed in the second half of 2025, subject to customary closing conditions Positive topline data from the completed fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) study of farabursen (RGLS8429) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Company on track for initiation of Phase 3 single pivotal trial in the third quarter 2025 SAN DIEGO, May 8, 2025 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. “We recently announced that we have entered into an agreement to be acquired by Novartis, whose established global development and commercial capabilities will potentially bring farabursen to patients with ADPKD, who currently have limited treatment options,” said Jay Hagan, CEO of Regulus Therapeutics.
Analysts’ Opinion of RGLS
Many brokerage firms have already submitted their reports for RGLS stocks, with Wells Fargo repeating the rating for RGLS by listing it as a “Overweight.” The predicted price for RGLS in the upcoming period, according to Wells Fargo is $6 based on the research report published on March 27, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see RGLS reach a price target of $7. The rating they have provided for RGLS stocks is “Outperform” according to the report published on August 02nd, 2024.
Leerink Partners gave a rating of “Outperform” to RGLS, setting the target price at $6 in the report published on March 18th of the previous year.
RGLS Trading at 132.22% from the 50-Day Moving Average
After a stumble in the market that brought RGLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.21% of loss for the given period.
Volatility was left at 6.49%, however, over the last 30 days, the volatility rate increased by 0.83%, as shares surge +281.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +473.36% upper at present.
During the last 5 trading sessions, RGLS fell by -0.19%, which changed the moving average for the period of 200-days by +324.59% in comparison to the 20-day moving average, which settled at $6.07. In addition, Regulus Therapeutics Inc saw 397.15% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGLS starting from Hagan Joseph P, who purchase 50,000 shares at the price of $1.09 back on Jan 30 ’25. After this action, Hagan Joseph P now owns 260,808 shares of Regulus Therapeutics Inc, valued at $54,260 using the latest closing price.
BALTIMORE DAVID, the Director of Regulus Therapeutics Inc, purchase 19,610 shares at $1.06 during a trade that took place back on Jan 30 ’25, which means that BALTIMORE DAVID is holding 22,169 shares at $20,787 based on the most recent closing price.
Stock Fundamentals for RGLS
The total capital return value is set at -0.73. Equity return is now at value -53.82, with -50.30 for asset returns.
Based on Regulus Therapeutics Inc (RGLS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -31.08. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -877.19.
Currently, EBITDA for the company is -45.85 million with net debt to EBITDA at 1.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.52.
Conclusion
In conclusion, Regulus Therapeutics Inc (RGLS) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
